Trial Profile

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; FT 500 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
Indications Carcinoma; Hodgkin's disease; Lymphoma; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms Landmark
Sponsors Fate Therapeutics

Most Recent Events

27 Jan 2023 Status changed from active, no longer recruiting to completed.
05 Oct 2022 According to Fate Therapeutics media release, results from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting 2022.
27 Sep 2022 Planned End Date changed from 1 Jul 2023 to 17 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com